Open AccessNational Survey of Extended-Interval Aminoglycoside Dosing in Pediatric Cystic Fibrosis Pulmonary Exacerbations
Author(s) -
William A. Prescott
Publication year - 2011
Publication title -
the journal of pediatric pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 15
eISSN - 2331-348X
pISSN - 1551-6776
DOI - 10.5863/1551-6776-16.4.262
Subject(s) - medicine , tobramycin , cystic fibrosis , dosing , aminoglycoside , ototoxicity , nephrotoxicity , therapeutic drug monitoring , population , intensive care medicine , pediatrics , antibiotics , gentamicin , pharmacokinetics , chemotherapy , environmental health , toxicity , microbiology and biotechnology , cisplatin , biology
The Cystic Fibrosis Foundation recently deemed the use of extended-interval dosing (EID) of aminoglycosides acceptable for the treatment of cystic fibrosis (CF) pulmonary exacerbations, but current practices across United States (US) pediatric CF accredited care centers and affiliate programs are unknown. The objectives of this research are to characterize the practice trends, dosing strategies, therapeutic drug monitoring practices, and adverse drug reaction monitoring of EID of aminoglycosides in the treatment of pulmonary exacerbations across US pediatric CF programs.